Skip to main content

2023 | OriginalPaper | Buchkapitel

9. Stimmungsstabilisatoren

verfasst von : Prof. Dr. rer. nat. Manfred Gerlach, Prof. Dr. med. Christoph Wewetzer

Erschienen in: Neuro-/Psychopharmaka im Kindes- und Jugendalter

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Die Wirkstoffklasse der Stimmungsstabilisatoren (englisch: mood stabiliser) ist eine chemisch und pharmakologisch heterogene Gruppe von Neuro‑/Psychopharmaka, die bei bipolaren Störungen zur Anwendung kommen. Stimmungsstabilisatoren beseitigen oder dämpfen u. a. die starken Stimmungsschwankungen, die mit den Krankheitsepisoden verbunden sind, sowie die Affektlabilität während und zwischen den Episoden. Zu den Stimmungsstabilisatoren gehören Lithiumsalze als klassische Vertreter sowie Antiepileptika mit stimmungsstabilisierenden Eingenschaften (wie Carbamazepin, Lamotrigin, Oxcarbazepin, Topiramat, Valproinsäure) und Antipsychotika der zweiten/dritten Generation (wie Aripiprazol, Asenapin, Cariprazin, Olanzapin, Quetiapin, Risperidon, Ziprasidon). In diesem Kapitel werden zunächst die Pharmakologie und Wirkungsmechanismen dieser Wirkstoffklasse dargestellt. Dann werden wichtige Aspekte der klinischen Psychopharmakologie wie Indikationen, klinische Wirksamkeit und Studienlage, Dosierungen, Pharmakawechselwirkungen, Kontraindikationen, Dauer der Behandlung und Kontrolluntersuchungen als Orientierungshilfe für die klinische Anwendung besprochen.
Literatur
Zurück zum Zitat Amaladoss A, Roberts N, Amaladoss F (2010) Evidence for use of mood stabilizers and anticonvulsants in the treatment on nonaffective disorders in children and adolescents. Clin Neuropharmacol 33:303–311PubMedCrossRef Amaladoss A, Roberts N, Amaladoss F (2010) Evidence for use of mood stabilizers and anticonvulsants in the treatment on nonaffective disorders in children and adolescents. Clin Neuropharmacol 33:303–311PubMedCrossRef
Zurück zum Zitat Amerio A, Ossola P, Scagnelli F et al. (2018) Safety and efficacy of lithium in children and adolescents: a systematic review in bipolar illness. Eur Psychiatry 54:85–97PubMedCrossRef Amerio A, Ossola P, Scagnelli F et al. (2018) Safety and efficacy of lithium in children and adolescents: a systematic review in bipolar illness. Eur Psychiatry 54:85–97PubMedCrossRef
Zurück zum Zitat Arzneimittelkommission der deutschen Ärzteschaft (2009) Arzneiverordnungen, 22. Aufl. Arzneimittelkommission, Berlin, S 1305 Arzneimittelkommission der deutschen Ärzteschaft (2009) Arzneiverordnungen, 22. Aufl. Arzneimittelkommission, Berlin, S 1305
Zurück zum Zitat Ashok AH, Marques TR, Jauhar S et al. (2017) The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry 22:666–679PubMedPubMedCentralCrossRef Ashok AH, Marques TR, Jauhar S et al. (2017) The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry 22:666–679PubMedPubMedCentralCrossRef
Zurück zum Zitat Atkin T, Nunez N, Gobbi G (2017) Practitioner Review: the effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder. J Child Psychol Psychiatry 58:865–879PubMedCrossRef Atkin T, Nunez N, Gobbi G (2017) Practitioner Review: the effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder. J Child Psychol Psychiatry 58:865–879PubMedCrossRef
Zurück zum Zitat Biederman J, Joshi G, Mick E et al. (2010) A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. CNS Neurosci Ther 16:91–102PubMedPubMedCentralCrossRef Biederman J, Joshi G, Mick E et al. (2010) A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. CNS Neurosci Ther 16:91–102PubMedPubMedCentralCrossRef
Zurück zum Zitat Bostwick JM, Pankratz VS (2000) Affective disorders and suicide risk: a reexamination. Am J Psychiat 157:1925–1932PubMedCrossRef Bostwick JM, Pankratz VS (2000) Affective disorders and suicide risk: a reexamination. Am J Psychiat 157:1925–1932PubMedCrossRef
Zurück zum Zitat Chang E, Saxena K, Howe M (2006) An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar disorders. J Am Acad Child Adolesc Psychiatry 45:298–304PubMedCrossRef Chang E, Saxena K, Howe M (2006) An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar disorders. J Am Acad Child Adolesc Psychiatry 45:298–304PubMedCrossRef
Zurück zum Zitat Chen TY, Kamali M, Chu CS et al. (2019) Divalproex and its effect on suicide risk in bipolar disorder: A systematic review and meta-analysis of multinational observational studies. J Affect Disord 245:812–818PubMedCrossRef Chen TY, Kamali M, Chu CS et al. (2019) Divalproex and its effect on suicide risk in bipolar disorder: A systematic review and meta-analysis of multinational observational studies. J Affect Disord 245:812–818PubMedCrossRef
Zurück zum Zitat Cole N, Parker G (2012) Cade’s identification of lithium for manic-depressive illness – The prospector who found a gold nugget. J Nerv Ment Dis 200:1101–1104PubMedCrossRef Cole N, Parker G (2012) Cade’s identification of lithium for manic-depressive illness – The prospector who found a gold nugget. J Nerv Ment Dis 200:1101–1104PubMedCrossRef
Zurück zum Zitat Comai S, Tau M, Pavlovic Z, Gobbi G (2012) The psychopharmacology of aggressive behavior: translational approach. Part 2: Clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Pschopharmacol 32:237–270 Comai S, Tau M, Pavlovic Z, Gobbi G (2012) The psychopharmacology of aggressive behavior: translational approach. Part 2: Clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Pschopharmacol 32:237–270
Zurück zum Zitat Correll CU, Sheridan EM, DelBello MP (2010) Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: A comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 12:116–141 Correll CU, Sheridan EM, DelBello MP (2010) Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: A comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 12:116–141
Zurück zum Zitat Cueva JE, Overall JE, Small AM et al. (1996) Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adol Psychiatry 35:480–490CrossRef Cueva JE, Overall JE, Small AM et al. (1996) Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adol Psychiatry 35:480–490CrossRef
Zurück zum Zitat Data-Franco J, Singh A, Popovic D et al. (2017) Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology. Progr Neuro Psychopharmacol Biol Psychiatry 72:73–86CrossRef Data-Franco J, Singh A, Popovic D et al. (2017) Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology. Progr Neuro Psychopharmacol Biol Psychiatry 72:73–86CrossRef
Zurück zum Zitat Davanzo P, Nikore V, Yehya N, Stevenson L (2004) Oxcarbazepine treatment of juvenile-onset bipolar disorder. J Child Adolesc Psychopharmacol 14:344–345PubMedCrossRef Davanzo P, Nikore V, Yehya N, Stevenson L (2004) Oxcarbazepine treatment of juvenile-onset bipolar disorder. J Child Adolesc Psychopharmacol 14:344–345PubMedCrossRef
Zurück zum Zitat DelBello MP, Goldman R, Phillips D et al. (2017) Efficacy and safety of Lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. J Am Acad Child Adol Psychiatry 56:1015–1025CrossRef DelBello MP, Goldman R, Phillips D et al. (2017) Efficacy and safety of Lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. J Am Acad Child Adol Psychiatry 56:1015–1025CrossRef
Zurück zum Zitat DelBello MP, Kadakia A, Heller V et al. (2022) Systematic review and network meta-analysis: efficacy and safety of seconde-generation antipsychotics in youths with bipolar depression. J Am Acad Child Adol Pschiatry 61:243–254CrossRef DelBello MP, Kadakia A, Heller V et al. (2022) Systematic review and network meta-analysis: efficacy and safety of seconde-generation antipsychotics in youths with bipolar depression. J Am Acad Child Adol Pschiatry 61:243–254CrossRef
Zurück zum Zitat Delbello MP, Kowatch RA, Warner J et al. (2002) Adjunctive topiramate treatment for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol 12:323–330PubMedCrossRef Delbello MP, Kowatch RA, Warner J et al. (2002) Adjunctive topiramate treatment for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol 12:323–330PubMedCrossRef
Zurück zum Zitat DelBello MP, Findling RL, Kushner S et al. (2005) A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Psy 44:539–554CrossRef DelBello MP, Findling RL, Kushner S et al. (2005) A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Psy 44:539–554CrossRef
Zurück zum Zitat DelBello MP, Kowatch RA, Adler CM et al. (2006) A double-blind, randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 45:305–313PubMedCrossRef DelBello MP, Kowatch RA, Adler CM et al. (2006) A double-blind, randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 45:305–313PubMedCrossRef
Zurück zum Zitat DelBello MP, Hanseman D, Adler CM, Fleck DE, Strakowski SM (2007) Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. Am J Psychiatry 164:582–590PubMedCrossRef DelBello MP, Hanseman D, Adler CM, Fleck DE, Strakowski SM (2007) Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. Am J Psychiatry 164:582–590PubMedCrossRef
Zurück zum Zitat Detke HC, DelBello MP, Landry J et al. (2015) Olanzapine/fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiar 54:217-224 Detke HC, DelBello MP, Landry J et al. (2015) Olanzapine/fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiar 54:217-224
Zurück zum Zitat Díaz-Caneja CM, Moreno C, Llorente C et al. (2014) Practitioner review: long-term pharmacological treatment of pediatric bipolar disorder. J Child Psychol Psychiatry 55:959–980PubMedCrossRef Díaz-Caneja CM, Moreno C, Llorente C et al. (2014) Practitioner review: long-term pharmacological treatment of pediatric bipolar disorder. J Child Psychol Psychiatry 55:959–980PubMedCrossRef
Zurück zum Zitat Dilsaver SC, Chen YW, Swann AC et al. (1997) Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Res 73:47–56PubMedCrossRef Dilsaver SC, Chen YW, Swann AC et al. (1997) Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Res 73:47–56PubMedCrossRef
Zurück zum Zitat Donovan S, Stewart J, Nunes E et al. (2000) Divalproex treatment for youth with explosive temper and mood lability: a double- blind, placebo-controlled crossover design. Am J Psychiatry 157:818–820PubMedCrossRef Donovan S, Stewart J, Nunes E et al. (2000) Divalproex treatment for youth with explosive temper and mood lability: a double- blind, placebo-controlled crossover design. Am J Psychiatry 157:818–820PubMedCrossRef
Zurück zum Zitat Duffy GP (2018) Lithium treatment in children and adolescents. Pharmacopsychiatry 51:189–193PubMedCrossRef Duffy GP (2018) Lithium treatment in children and adolescents. Pharmacopsychiatry 51:189–193PubMedCrossRef
Zurück zum Zitat Duffy A, Heffer N, Goodday SM et al. (2018) Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: a systematic review: a report from the ISBD-IGSLi joint task force on lithium treatment. Bipolar Disord 20:583–593PubMedCrossRef Duffy A, Heffer N, Goodday SM et al. (2018) Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: a systematic review: a report from the ISBD-IGSLi joint task force on lithium treatment. Bipolar Disord 20:583–593PubMedCrossRef
Zurück zum Zitat Findling RL, Ginsberg LD (2014) The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode. Neuropsychiatr Dis Treat 10:1589–1597PubMedPubMedCentralCrossRef Findling RL, Ginsberg LD (2014) The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode. Neuropsychiatr Dis Treat 10:1589–1597PubMedPubMedCentralCrossRef
Zurück zum Zitat Findling RL, McNamara NK, Youngstrom EA et al. (2005) Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Psy 44:409–417CrossRef Findling RL, McNamara NK, Youngstrom EA et al. (2005) Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Psy 44:409–417CrossRef
Zurück zum Zitat Findling RL, McNamara NK, Stansbrey R et al. (2006) Combination lithium and divalproex sodium in pediatric bipolar symptom restabilization. J Am Acad Child Psy 45:142–148CrossRef Findling RL, McNamara NK, Stansbrey R et al. (2006) Combination lithium and divalproex sodium in pediatric bipolar symptom restabilization. J Am Acad Child Psy 45:142–148CrossRef
Zurück zum Zitat Findling RL, Youngstrom EA, McNamara NK et al (2012) Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder. J Clin Psychiatry 73:57–63PubMedCrossRef Findling RL, Youngstrom EA, McNamara NK et al (2012) Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder. J Clin Psychiatry 73:57–63PubMedCrossRef
Zurück zum Zitat Findling RL, Kafantaris V, Pavuluri M et al. (2013) Post-acute effectiveness of lithium in pediatric bipolar I disorder. J Child Adol Psychop 23:80–90CrossRef Findling RL, Kafantaris V, Pavuluri M et al. (2013) Post-acute effectiveness of lithium in pediatric bipolar I disorder. J Child Adol Psychop 23:80–90CrossRef
Zurück zum Zitat Findling RL, Chang K, Robb A et al. (2015a) Adjunctive maintenance lamotrigine for pedatric bipolar I disorder: a placebo-controlles, randomized withdrawal study. J Am Acad Child Adol Pschiatry 54:1020–1031CrossRef Findling RL, Chang K, Robb A et al. (2015a) Adjunctive maintenance lamotrigine for pedatric bipolar I disorder: a placebo-controlles, randomized withdrawal study. J Am Acad Child Adol Pschiatry 54:1020–1031CrossRef
Zurück zum Zitat Findling RL, Robb A, McNamara NK et al. (2015b) Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study. Pediatrics 136:885–894PubMedPubMedCentralCrossRef Findling RL, Robb A, McNamara NK et al. (2015b) Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study. Pediatrics 136:885–894PubMedPubMedCentralCrossRef
Zurück zum Zitat Geller B, Couper TB, Sun K et al. (1998) Double-blind- and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Psy 37:171–178CrossRef Geller B, Couper TB, Sun K et al. (1998) Double-blind- and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Psy 37:171–178CrossRef
Zurück zum Zitat Geller B, Luby JL, Joshi P et al. (2012) A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiat 69:515–528PubMedCrossRef Geller B, Luby JL, Joshi P et al. (2012) A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiat 69:515–528PubMedCrossRef
Zurück zum Zitat Gerlach M (2021) Pharmakologische und rechtliche Grundkenntnisse der Psychopharmakotherapie. Psych Up2date 15:71–84CrossRef Gerlach M (2021) Pharmakologische und rechtliche Grundkenntnisse der Psychopharmakotherapie. Psych Up2date 15:71–84CrossRef
Zurück zum Zitat Gerlach M, Baving L, Fegert J (2006) Therapie mit Lithium-Salzen in der Kinder- und Jugendpsychiatrie – Klinische Wirksamkeit und praktische Empfehlungen. Z Kinder Jugendpsychiatrie 34:181–189CrossRef Gerlach M, Baving L, Fegert J (2006) Therapie mit Lithium-Salzen in der Kinder- und Jugendpsychiatrie – Klinische Wirksamkeit und praktische Empfehlungen. Z Kinder Jugendpsychiatrie 34:181–189CrossRef
Zurück zum Zitat Gerlach M, Warnke A (2010) Therapy with mood stabilizers in child and adolescent psychiatry. Psychopharmakotherapie 17:183–187 Gerlach M, Warnke A (2010) Therapy with mood stabilizers in child and adolescent psychiatry. Psychopharmakotherapie 17:183–187
Zurück zum Zitat Gerstner T, Busing D, Bell N et al. (2007) Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 42:39–48PubMedCrossRef Gerstner T, Busing D, Bell N et al. (2007) Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 42:39–48PubMedCrossRef
Zurück zum Zitat Grunze H, Müller WE (2020) Weiterbildungs-Curriculum Psychopharmakologie/Pharmakotherapie. Teil 12: Stimmungsstabilisierer – I: Antiepileptika und atypische Antipsychotika. Psychopharmakotherapie 27:62–75 Grunze H, Müller WE (2020) Weiterbildungs-Curriculum Psychopharmakologie/Pharmakotherapie. Teil 12: Stimmungsstabilisierer – I: Antiepileptika und atypische Antipsychotika. Psychopharmakotherapie 27:62–75
Zurück zum Zitat Grunze H, Severus E, Laux G, Müller WE (2020) Weiterbildungs-Curriculum Psychopharmakologie/Pharmakotherapie. Teil 12: Stimmungsstabilisierer – II: Lithium. Psychopharmakotherapie 27:149–155 Grunze H, Severus E, Laux G, Müller WE (2020) Weiterbildungs-Curriculum Psychopharmakologie/Pharmakotherapie. Teil 12: Stimmungsstabilisierer – II: Lithium. Psychopharmakotherapie 27:149–155
Zurück zum Zitat Hachad H, Ragueneau-Majlessi I, Levy RH (2002) New antiepileptic drugs: review on drug interactions. Ther Drug Monit 24:91–103PubMedCrossRef Hachad H, Ragueneau-Majlessi I, Levy RH (2002) New antiepileptic drugs: review on drug interactions. Ther Drug Monit 24:91–103PubMedCrossRef
Zurück zum Zitat Hafeman DM, Rooks B, Merranko J et al. (2020) Lithium versus other mood-stabilizing medications in a longitudinal study of youth diagnosed with bipolar disorder. J Am Acad Child Adol Psychiatry 59:1146–1155CrossRef Hafeman DM, Rooks B, Merranko J et al. (2020) Lithium versus other mood-stabilizing medications in a longitudinal study of youth diagnosed with bipolar disorder. J Am Acad Child Adol Psychiatry 59:1146–1155CrossRef
Zurück zum Zitat Hazell P, Jairam R (2012) Acute treatment of mania in children and adolescents. Curr Opin Psychiatr 25:264–270CrossRef Hazell P, Jairam R (2012) Acute treatment of mania in children and adolescents. Curr Opin Psychiatr 25:264–270CrossRef
Zurück zum Zitat Hegerl U, Hensch T (2014) The vigilance regulation model of affective disorders and ADHD. Neurosci Biobehav Rev 44: 45–57 Hegerl U, Hensch T (2014) The vigilance regulation model of affective disorders and ADHD. Neurosci Biobehav Rev 44: 45–57
Zurück zum Zitat Hellings JA, Weckbaugh M, Nickel EJ et al. (2005) A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 15:682–692PubMedCrossRef Hellings JA, Weckbaugh M, Nickel EJ et al. (2005) A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 15:682–692PubMedCrossRef
Zurück zum Zitat Hollander E, Soorya L, Wasserman S et al. (2006) Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 9:209–213PubMedCrossRef Hollander E, Soorya L, Wasserman S et al. (2006) Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 9:209–213PubMedCrossRef
Zurück zum Zitat Hollander E, Chaplin W, Soorya L et al. (2010) Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacol 35:990–998CrossRef Hollander E, Chaplin W, Soorya L et al. (2010) Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacol 35:990–998CrossRef
Zurück zum Zitat Holtmann M, Krause M, Opp J et al. (2002) Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children. Neuropediatrics 33:298–300PubMedCrossRef Holtmann M, Krause M, Opp J et al. (2002) Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children. Neuropediatrics 33:298–300PubMedCrossRef
Zurück zum Zitat Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV (1993) Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. New Engl J Med 329:1383–1388PubMedCrossRef Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV (1993) Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. New Engl J Med 329:1383–1388PubMedCrossRef
Zurück zum Zitat Joshi G, Wozniak J, Mick E et al. (2010) A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. J Child Adol Psychop 20:7–14CrossRef Joshi G, Wozniak J, Mick E et al. (2010) A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. J Child Adol Psychop 20:7–14CrossRef
Zurück zum Zitat Kowatch RA, Suppes T, Carmody TJ et al. (2000) Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Psy 39:713–720CrossRef Kowatch RA, Suppes T, Carmody TJ et al. (2000) Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Psy 39:713–720CrossRef
Zurück zum Zitat Kowatch RA, Sethuraman G, Hume JH, Kromelis M, Weinberg WA (2003) Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiat 53:978–984PubMedCrossRef Kowatch RA, Sethuraman G, Hume JH, Kromelis M, Weinberg WA (2003) Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiat 53:978–984PubMedCrossRef
Zurück zum Zitat Kowatch RA, Fristad M, Birmaher B et al. (2005) Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Psy 44:213–235 (The Child Psychiatric Workgroup on Bipolar Disorder)CrossRef Kowatch RA, Fristad M, Birmaher B et al. (2005) Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Psy 44:213–235 (The Child Psychiatric Workgroup on Bipolar Disorder)CrossRef
Zurück zum Zitat Landgraf D, Joiner WJ, McCarthy MJ et al. (2016) The mood stabilizer valproic acid opposes the effects of dopamine on circadian rhythms. Neuropharmacology 107:262–270PubMedCrossRef Landgraf D, Joiner WJ, McCarthy MJ et al. (2016) The mood stabilizer valproic acid opposes the effects of dopamine on circadian rhythms. Neuropharmacology 107:262–270PubMedCrossRef
Zurück zum Zitat Liu HY, Potter MP, Woodworth KY et al. (2011) Pharmacologic treatment for pediatric bipolar disorder: a meta-analysis. J Am Acad Child Psy 50:749–762CrossRef Liu HY, Potter MP, Woodworth KY et al. (2011) Pharmacologic treatment for pediatric bipolar disorder: a meta-analysis. J Am Acad Child Psy 50:749–762CrossRef
Zurück zum Zitat Malone EP, Delaney MA, Luebbert JF, Cater J, Campbell M (2000) A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 57:649–655PubMedCrossRef Malone EP, Delaney MA, Luebbert JF, Cater J, Campbell M (2000) A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 57:649–655PubMedCrossRef
Zurück zum Zitat McCarthy MJ, Wie H, Nievergelt CM et al. (2019) Chronotype and cellular circadian rhythms predict the clinical response to lithium maintanance treatment in patients with bipolar disorder. Neuropsychopharmacology 44:620–628PubMedCrossRef McCarthy MJ, Wie H, Nievergelt CM et al. (2019) Chronotype and cellular circadian rhythms predict the clinical response to lithium maintanance treatment in patients with bipolar disorder. Neuropsychopharmacology 44:620–628PubMedCrossRef
Zurück zum Zitat McClellan J, Kowatch R, Findling RL (2007) Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Psy 46:107–125CrossRef McClellan J, Kowatch R, Findling RL (2007) Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Psy 46:107–125CrossRef
Zurück zum Zitat McKnight RF, Adida M, Budge K et al. (2012) Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379:721–728PubMedCrossRef McKnight RF, Adida M, Budge K et al. (2012) Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379:721–728PubMedCrossRef
Zurück zum Zitat Mishra HK, Ying NM, Luis A et al. (2021) Circadian rhythms in bipolar disorder patient-derived neurons predict lithium response: preliminary studies. Mol Psychiatry 26:3383–3394PubMedPubMedCentralCrossRef Mishra HK, Ying NM, Luis A et al. (2021) Circadian rhythms in bipolar disorder patient-derived neurons predict lithium response: preliminary studies. Mol Psychiatry 26:3383–3394PubMedPubMedCentralCrossRef
Zurück zum Zitat Moll GH, Rothenberger A (1998) Lithiumsalze in der Kinder- und Jugendpsychiatrie. Nervenarzt 69:935–994 Moll GH, Rothenberger A (1998) Lithiumsalze in der Kinder- und Jugendpsychiatrie. Nervenarzt 69:935–994
Zurück zum Zitat Moore CM, Demopulos CM, Henry ME et al. (2002) Brain-to-serum lithium ratio and age: an in vivo magnetic resonance spectroscopy study. Am J Psychiatry 159:1240–1242PubMedPubMedCentralCrossRef Moore CM, Demopulos CM, Henry ME et al. (2002) Brain-to-serum lithium ratio and age: an in vivo magnetic resonance spectroscopy study. Am J Psychiatry 159:1240–1242PubMedPubMedCentralCrossRef
Zurück zum Zitat Nolen WA, Licht RW, Young AH et al. (2019) What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? a systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. Bipolar Disord 21:394–409PubMedPubMedCentralCrossRef Nolen WA, Licht RW, Young AH et al. (2019) What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? a systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. Bipolar Disord 21:394–409PubMedPubMedCentralCrossRef
Zurück zum Zitat Patel NC, Delbello MP, Bryan HS et al. (2006) Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Psy 45:289–297CrossRef Patel NC, Delbello MP, Bryan HS et al. (2006) Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Psy 45:289–297CrossRef
Zurück zum Zitat Patino LR, Klein CC, Strawn JR et al. (2021) A randomized, double-blind, controlled trial of lithium versus quetiapine for the treatment of acute mania in youth with early course bipolar disorder. J Child Adol Psychopharmacol 31:485–489CrossRef Patino LR, Klein CC, Strawn JR et al. (2021) A randomized, double-blind, controlled trial of lithium versus quetiapine for the treatment of acute mania in youth with early course bipolar disorder. J Child Adol Psychopharmacol 31:485–489CrossRef
Zurück zum Zitat Pavuluri MN, Henry DB, Carbray JA et al. (2004) Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord 82:103–S111CrossRef Pavuluri MN, Henry DB, Carbray JA et al. (2004) Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord 82:103–S111CrossRef
Zurück zum Zitat Pavuluri MN, Henry DB, Carbray JA et al. (2006) A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. J Child Adol Psychop 16:336–350CrossRef Pavuluri MN, Henry DB, Carbray JA et al. (2006) A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. J Child Adol Psychop 16:336–350CrossRef
Zurück zum Zitat Pavuluri MN, Henry DB, Moss M et al. (2009) Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder. J Child Adolesc Pschopharmacol 19:75–82 Pavuluri MN, Henry DB, Moss M et al. (2009) Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder. J Child Adolesc Pschopharmacol 19:75–82
Zurück zum Zitat Salpekar JA, Joshi PT, Axelson DA et al. (2015) Depression and suicidality outcomes in the treatment of early age mania study. J Am Acad Child Adol Psychiatry 54:999–1007CrossRef Salpekar JA, Joshi PT, Axelson DA et al. (2015) Depression and suicidality outcomes in the treatment of early age mania study. J Am Acad Child Adol Psychiatry 54:999–1007CrossRef
Zurück zum Zitat Schatzberg AF, Cole JO, de Battista C (2003) Manual of clinical psychopharmacology, 4. Aufl. American Psychiatric Publishing, Washington Schatzberg AF, Cole JO, de Battista C (2003) Manual of clinical psychopharmacology, 4. Aufl. American Psychiatric Publishing, Washington
Zurück zum Zitat Schloesser RJ, Martinowich K, Manji HK (2012) Mood-stabilizing drugs: mechanism of action. Trends Neurosci 35:36–46PubMedCrossRef Schloesser RJ, Martinowich K, Manji HK (2012) Mood-stabilizing drugs: mechanism of action. Trends Neurosci 35:36–46PubMedCrossRef
Zurück zum Zitat Segal HD, Salgado BR, Garcia AC, Cabases JS (2006) Efficacy of topiramate in children and adolescents with problems in impulse control: preliminary results. Actas Esp Psiquiatr 34:280–282 Segal HD, Salgado BR, Garcia AC, Cabases JS (2006) Efficacy of topiramate in children and adolescents with problems in impulse control: preliminary results. Actas Esp Psiquiatr 34:280–282
Zurück zum Zitat Strober M, Morrell W, Lampert C, Burroughs J (1990) Relapse following discontinuation of lithium maintenance therapy in adolescents with bipolar I illness: a naturalistic study. Am J Psychiatry 147:457–461PubMedCrossRef Strober M, Morrell W, Lampert C, Burroughs J (1990) Relapse following discontinuation of lithium maintenance therapy in adolescents with bipolar I illness: a naturalistic study. Am J Psychiatry 147:457–461PubMedCrossRef
Zurück zum Zitat Stepanova E, Findling RL (2017) Psychopharmacology of bipolar disorders in children and adolescents. Ped Clin N Am 64:1209CrossRef Stepanova E, Findling RL (2017) Psychopharmacology of bipolar disorders in children and adolescents. Ped Clin N Am 64:1209CrossRef
Zurück zum Zitat Teitelbaum M (2001) Oxcarbazepine in bipolar disorder. J Am Acad Child Adolesc Psychiatry 40:993–994PubMedCrossRef Teitelbaum M (2001) Oxcarbazepine in bipolar disorder. J Am Acad Child Adolesc Psychiatry 40:993–994PubMedCrossRef
Zurück zum Zitat Tramontina S, Zeni CP, Pheula G, Rohde LA (2007) Topiramate in adolescents with juvenile bipolar disorder presenting weight gain due to atypical antipsychotics or mood stabilizers: an open clinical trial. J Child Adol Psychop 17:129–134CrossRef Tramontina S, Zeni CP, Pheula G, Rohde LA (2007) Topiramate in adolescents with juvenile bipolar disorder presenting weight gain due to atypical antipsychotics or mood stabilizers: an open clinical trial. J Child Adol Psychop 17:129–134CrossRef
Zurück zum Zitat Vloet JA, Hagenah UF (2009) Pharmakotherapie bipolarer Störungen im Kindes- und Jugendalter. Z Kinder Jugendpyschiatr Psychother 37:27–50CrossRef Vloet JA, Hagenah UF (2009) Pharmakotherapie bipolarer Störungen im Kindes- und Jugendalter. Z Kinder Jugendpyschiatr Psychother 37:27–50CrossRef
Zurück zum Zitat Wagner KD, Kowatch RA, Emslie GJ et al. (2006) A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiat 163:1179–1186PubMedCrossRef Wagner KD, Kowatch RA, Emslie GJ et al. (2006) A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiat 163:1179–1186PubMedCrossRef
Zurück zum Zitat Wozniak J, Mick E, Waxmonsky J et al. (2009) Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol 19:539–554PubMedCrossRef Wozniak J, Mick E, Waxmonsky J et al. (2009) Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol 19:539–554PubMedCrossRef
Zurück zum Zitat Stepanova E, Findling RL (2017) Psychopharmacology of bipolar disorders in children and adolescents. Ped Clin N Am 64:1209–1222 CrossRef Stepanova E, Findling RL (2017) Psychopharmacology of bipolar disorders in children and adolescents. Ped Clin N Am 64:1209–1222 CrossRef
Metadaten
Titel
Stimmungsstabilisatoren
verfasst von
Prof. Dr. rer. nat. Manfred Gerlach
Prof. Dr. med. Christoph Wewetzer
Copyright-Jahr
2023
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-65267-1_9

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).